Plixorafenib

Plixorafenib (FORE8394, formerly PLX8394) is Fore Biotherapeutics' oral small-molecule BRAF inhibitor being tested in a Phase 2 master protocol (FORTE, NCT05503797) across BRAF-altered solid tumors and primary CNS tumors [1]. The compound belongs to a second-generation class known as paradox breakers, designed to block mutant BRAF signaling without the wildtype MAPK activation that has capped first-generation inhibitors [2]. Fore, a private company that inherited the asset from Plexxikon's legacy program, is betting on differentiated activity against class 2 (dimer-forming) BRAF alterations and BRAF fusions, populations largely locked out of the existing vemurafenib, dabrafenib, and encorafenib franchise. Phase 1/2a produced credible CNS responses that earned FDA Breakthrough Therapy Designation in April 2026 for adult BRAF V600E high-grade glioma, believed to be the first targeted-therapy BTD in that indication [10]. If registrational readouts hold, this is a niche but real opportunity in adult solid tumors and glioma. If they do not, the pediatric BRAF-altered glioma market is already occupied by Day One's tovorafenib (Ojemda), approved by FDA in April 2024 [3].

This is a novel investigational compound, never approved anywhere. The lead trial is FORTE (NCT05503797), a Phase 2 open-label master protocol recruiting up to 254 participants across three subprotocols: adult solid tumors excluding CNS (A), primary CNS tumors including recurrent and progressive glioma (B), and pediatric patients (C) [1]. The primary endpoint is investigator-assessed objective response rate (ORR, the fraction of patients whose tumors shrink by a predefined amount) by RECIST 1.1 for solid tumors or RANO for CNS. Fore has disclosed FDA Fast Track designation, Orphan Drug designation for BRAF V600E glioma, and in April 2026 a Breakthrough Therapy Designation for adult BRAF V600E high-grade glioma based on Phase 1/2a data [10]. A separate investigator-sponsored study at Johns Hopkins (NCT06610682) is testing plixorafenib alone or with retifanlimab (a PD-1 checkpoint inhibitor) in BRAF-altered glioma, using cerebrospinal fluid circulating tumor DNA (ctDNA, tumor DNA shed into body fluids used as a real-time biopsy proxy) as a pharmacodynamic readout [5]. A completed Phase 1 pharmacokinetic study (NCT06385119) evaluated food and cobicistat effects in healthy volunteers [6]; cobicistat is a CYP3A4 inhibitor used deliberately as a pharmacokinetic booster in the plixorafenib regimen (with-cobicistat arms were evaluated in the pivotal Phase 1/2a), not merely a drug-drug interaction concern. Phase 1 clinical proof-of-concept came from NCT02428712, a Phase 1/2a study of oral plixorafenib at 900 to 3600 mg/day with or without cobicistat in 108 adults and 5 children with BRAF-altered solid tumors [11]. Among 9 evaluable MAPK-inhibitor-naive adults with BRAF V600E primary CNS tumors, ORR was 67% (6/9), including 4/5 high-grade gliomas and 2/4 low-grade gliomas or glial-neuronal tumors, with a median duration of response of 13.9 months. Across V600-altered solid tumors overall, ORR was 42% (10/24) in the MAPKi-naive non-colorectal cohort with 1-year progression-free survival of 54.4%. These CNS responses, including in patients with non-enhancing lesions and pilocytic astrocytoma, are the direct biological evidence of clinically meaningful blood-brain barrier penetration, a differentiator from first-generation vemurafenib and dabrafenib, which are P-glycoprotein substrates with limited CNS exposure. Fore has publicly guided that topline data from the FORTE recurrent BRAF V600E primary CNS tumor basket is expected around the end of 2026 [10]. On the balance sheet, Fore remains private but announced closing of an upsized Series D-2 extension of $67.4 million in July 2026, bringing total Series D-2 financing to approximately $110 million and extending cash runway through the CNS basket topline [10].

BRAF is a protein kinase, a molecular switch that relays growth signals from the cell surface toward the nucleus. When mutated, it can get stuck in the on position and drive uncontrolled cell division. Class 1 mutations (V600E and V600K) act as monomers; class 2 mutations (G469A, K601E, L597, and fusion partners) form constitutively active dimers; class 3 mutations are kinase-impaired but rely on upstream RAS signaling [2]. First-generation BRAF inhibitors (vemurafenib, dabrafenib, encorafenib) hit monomeric V600E cleanly but do something worse than nothing in wildtype-BRAF cells. They trigger paradoxical MAPK activation, which is why patients on these drugs develop cutaneous squamous cell carcinomas and why the drugs fail in class 2 and class 3 disease [2]. Plixorafenib was engineered to bind BRAF in a way that disrupts dimer formation rather than stabilizing it, blocking monomeric mutant BRAF and class 2 dimers without paradoxically activating wildtype signaling [2]. This paradox breaker concept came out of Plexxikon (the same shop that invented vemurafenib) and rests on solid genetic and biochemical support. Equally important for the CNS thesis, plixorafenib appears to cross the blood-brain barrier at exposures sufficient to drive tumor responses. Phase 1/2a produced radiographic responses in primary CNS tumors, including non-enhancing (blood-brain-barrier-intact) lesions and pilocytic astrocytoma, evidence that circulating drug reaches intact brain parenchyma at active concentrations [11]. This is a distinct profile from vemurafenib and dabrafenib, whose CNS penetration is limited by P-glycoprotein efflux, and it sits alongside tovorafenib (Day One's Ojemda), the other CNS-penetrant type II RAF inhibitor already approved for pediatric BRAF-altered low-grade glioma [3]. The open question is whether the chemistry translates to durable responses in adult classes and fusion-driven tumors that do not fit the V600E box.

FORTE (NCT05503797) is a Phase 2 open-label single-arm master protocol with three subprotocols covering distinct populations: subprotocol A enrolls adults with BRAF-altered advanced or metastatic solid tumors excluding primary CNS tumors, subprotocol B covers primary CNS tumors including recurrent and progressive glioma, and subprotocol C is pediatric [1]. The eligibility net is intentionally wide: class 1 (V600) and class 2 BRAF alterations plus BRAF fusions, with enrichment for patients who have progressed on prior BRAF-targeted therapy or who lack an approved BRAF option. The primary endpoint is ORR by RECIST 1.1 (a standardized ruler for measuring tumor shrinkage on scans in solid tumors) or RANO (the CNS-adapted equivalent used for brain tumors). Target enrollment is 254 participants globally. Secondary endpoints include duration of response, progression-free survival, and safety. Structurally this is a reasonable Phase 2 for a rare-molecular-alteration franchise: single-arm, response-based, tumor-agnostic, similar to how larotrectinib and selpercatinib built their initial approvals. The concern is that pooled ORR across a heterogeneous tumor mix can flatter or hide meaningful signal at the subtype level. Public data cuts have been small and selective. A large disciplined data drop with per-alteration breakouts (class 2 vs fusion vs post-vemurafenib V600E) is what would actually settle the question.

Our model estimates a 12% chance this drug is eventually approved. It starts from the historical base rate for Phase 2 drugs in this area (about 13%), then adjusts using ten facts about the trial and sponsor. What moves the number most: it is helped by a non-randomized design and more secondary endpoints than usual; it is held back by the sponsor's thin or weak approval record and weak or limited earlier-phase results. The other facts land near average for this stage, so they leave the estimate roughly where the base rate put it.

Efficacy risk is the biggest. Plixorafenib's differentiation depends on activity in class 2 BRAF alterations and BRAF fusions, populations that are small individually and hard to enroll at scale. Belvarafenib, a competing pan-RAF inhibitor developed by Hanmi and licensed to Genentech, showed responses in this space but was hampered by hepatotoxicity that limited dosing [8]. On-target skin toxicity (photosensitivity, rash) and off-target liver signals are class concerns for RAF inhibitors and could narrow the therapeutic window. Regimen risk: the clinical dose relies on cobicistat as a CYP3A4 booster to achieve adequate plasma exposure, which introduces polypharmacy constraints (many oncology comedications interact with CYP3A4) that could complicate real-world use. Regulatory risk: an accelerated approval based on ORR in a tumor-agnostic BRAF-altered population is plausible, and BTD in adult V600E HGG improves the path there, but ODAC scrutiny of similar single-arm oncology filings across 2023 and 2024 has raised the bar on confirmatory design and duration of response. Commercial risk: even a clean approval faces a crowded BRAF market. Vemurafenib, dabrafenib, and encorafenib own class 1 V600E in melanoma and colorectal cancer. Tovorafenib (Day One's Ojemda) captured pediatric BRAF-altered glioma with a 2024 approval and generated roughly $91 million in 2024 revenue [9]. Payer pressure on tumor-agnostic pricing is real. Execution risk: Fore is private, and while the July 2026 Series D-2 extension ($67.4M, bringing total D-2 to ~$110M) extends runway through the FORTE CNS basket topline expected around end of 2026 [10], a Phase 3 program will require significant additional capital or a partnership.

Worth watching, with the CNS basket the most watchable data event. Plixorafenib's scientific premise (paradox-breaking chemistry, class 2 BRAF and fusion coverage, meaningful CNS penetration) is legitimate and differentiated, and Phase 1/2a's 67% CNS V600E ORR with 13.9-month median duration of response gave the FDA enough to grant Breakthrough Therapy Designation in April 2026 [10, 11]. The near-term data event is the FORTE recurrent BRAF V600E primary CNS tumor basket topline, which Fore has guided to around end of 2026. ASCO 2026 has already passed (June); check ASCO 2026 abstract archives for any interim FORTE subprotocol updates, and the Society for Neuro-Oncology meeting in November 2026 is the natural venue for CNS basket data ahead of the year-end topline. The specific data point that would flip this from interesting to actionable is a disciplined ORR readout in the class 2 BRAF and BRAF-fusion subcohorts of FORTE, ideally 40% or better with responses lasting six months or longer. Anything below 25% pooled across those subsets, or a hepatotoxicity signature reminiscent of belvarafenib, and the story compresses fast. Addressable-population context: BRAF is altered in roughly 3-4% of pan-cancer cohorts; class 2 mutations account for roughly 15% of BRAF-mutant tumors and fusions roughly 4%, with the highest absolute counts in melanoma, colorectal, and NSCLC (with NSCLC BRAF fusions specifically at ~0.2% of NSCLC), plus the near-universal BRAF fusion in pilocytic astrocytoma [12]. Fore being private means the commercial signal will come from press releases, investor R&D days, and any registration-directed cohort announcements rather than 10-K or 10-Q filings. A licensing or acquisition event by a larger oncology player (Pfizer, Novartis, or a BRAF-franchise incumbent) would also validate the program independent of trial-level data. Until then, plixorafenib sits in the biology-plausible, commercial-path-narrow bucket. It is the kind of asset that either becomes a genuinely useful niche drug or gets quietly wound down after two more years of underwhelming subcohort updates.